Consensus Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 20:24:03 14/07/2025 BST			5-day change	1st Jan Change
39.50 ^USD	+1.39%		+10.61%	+21.93%

07-09	US lawmakers renew concerns about GenScript's ties to China	RE
07-07	RBC Lowers Price Target on Legend Biotech to $75 From $78, Keeps Outperform Rating	MT

Evolution of the Average Target: Legend Biotech Corporation

Evolution of the Target Price: Legend Biotech Corporation

Changes in Analyst Recommendations: Legend Biotech Corporation

2ef42fb9626826d04f87267e84e.-pP8DEif4ms6L29qFZnn7bWatmpz2wngroJgd2oo8qQ.sv6-WDnwpVpAGV4tLdzKnfnTgwYesG2m_-EsHQZkmdTIoa9AGNDQMV96AA~871ce5dd0deccde15df6903316ed1e68

Analysts' recommendations: Legend Biotech Corporation

RBC Lowers Price Target on Legend Biotech to $75 From $78, Keeps Outperform Rating	07-07	MT
UBS Lowers Price Target on Legend Biotech to $54 From $60, Maintains Buy Rating	07-03	MT
Truist Securities Adjusts Legend Biotech Price Target to $71 From $88, Maintains Buy Rating	05-14	MT
RBC Trims Price Target on Legend Biotech to $84 From $86, Keeps Outperform Rating	01-07	MT
UBS Lowers Legend Biotech Price Target to $65 From $75, Maintains Buy Rating	12-09	MT
Redburn Initiates Legend Biotech at Buy With $86 Price Target	08/10/24	MT
TD Cowen Adjusts Legend Biotech Price Target to $67 From $71, Maintains Buy Rating	15/07/24	MT
Truist Securities Initiates Legend Biotech With Buy Rating, $88 Price Target	17/06/24	MT
HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating	24/05/24	MT
Deutsche Bank Starts Legend Biotech With Buy Rating	24/05/24	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating	14/05/24	MT
RBC Adjusts Price Target on Legend Biotech to $86 From $85 on Model Updates, Maintains Outperform Rating	14/05/24	MT
Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65	17/04/24	MT
Cantor Fitzgerald Initiates Legend Biotech With Overweight Rating	03/04/24	MT
UBS Adjusts Legend Biotech Price Target to $81 From $76, Maintains Buy Rating	18/03/24	MT
Raymond James Starts Legend Biotech With Outperform Rating, $86 Price Target	13/03/24	MT
RBC Trims Price Target on Legend Biotech to $85 From $86, Keeps Outperform Rating	03/01/24	MT
Scotiabank Initiates Legend Biotech With Sector Perform Rating, $65 Price Target	19/12/23	MT
HC Wainwright Raises Price Target on Legend Biotech to $87 From $86, Keeps Buy Rating	15/11/23	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $85, Keeps Buy Rating	18/10/23	MT
Barclays Adjusts Price Target on Legend Biotech to $93 From $92, Maintains Overweight Rating	18/10/23	MT
Barclays Adjusts Price Target on Legend Biotech to $92 From $90, Maintains Overweight Rating	21/07/23	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $85 From $82, Maintains Buy Rating	21/07/23	MT
Morgan Stanley Raises Price Target on Legend Biotech to $85 From $65, Maintains Overweight Rating	20/07/23	MT
BTIG Raises Price Target on Legend Biotech to $90 From $85, Maintains Buy Rating	13/06/23	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus (Composite)	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Ecart obj. / dr
	LEGEND BIOTECH CORPORATION					+92.81%
	ARGENX SE					+38.34%
	WUXI APPTEC CO., LTD.					+8.53%
	BIONTECH SE					+20.71%
	INSMED INCORPORATED					+15.31%
	SUMMIT THERAPEUTICS INC.					+40.11%
	WUXI BIOLOGICS (CAYMAN) INC.					+12.16%
	GENMAB A/S					+39.97%
	AKESO, INC.					-6.14%
	EXELIXIS, INC.					+2.19%
	Average					+26.40%
	Weighted average by Cap.					+23.72%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

38.96USD

Average target price

75.12USD

Spread / Average Target

+92.81%

High Price Target

94.00USD

Spread / Highest target

+141.27%

Low Price Target

53.12USD

Spread / Lowest Target

+36.34%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
UBS
Truist Securities
Redburn Atlantic
HC Wainwright
Deutsche Bank Securities
Scotiabank
Cantor Fitzgerald
Raymond James
Barclays
Morgan Stanley
BTIG
William Blair & Co.
Daiwa Securities
BMO Capital
JPMorgan Chase
Piper Sandler
Cowen
Guggenheim